Short Interest in CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Rises By 161.2%

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) was the recipient of a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 138,254 shares, a growth of 161.2% from the May 14th total of 52,933 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 1,432,012 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

CSLLY has been the topic of several recent research reports. Zacks Research cut CSL from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Jefferies Financial Group cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Citigroup cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Canaccord Genuity Group cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.

CSL Stock Performance

Shares of CSLLY stock traded down $0.07 during mid-day trading on Friday, reaching $19.08. 247,197 shares of the stock traded hands, compared to its average volume of 444,235. The stock’s fifty day simple moving average is $20.77 and its two-hundred day simple moving average is $40.12. CSL has a 1-year low of $16.01 and a 1-year high of $44.86. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.